Expression Therapeutics, Inc., has presented the results of a Phase 1 clinical trial for its novel lentiviral vector-based gene therapy ? ET3 ? for hemophilia A at the Annual Meeting of the American ...

ESO-T01 is the first in vivo BCMA CAR-T candidate to reach the clinical stageEarly clinical data are expected in second half of ...

Rarimo, a zero-knowledge (ZK) identity protocol, has announced the closing of a $2.5 million fundraising round spearheaded by ...

Vyriad's targeted lentiviral vector platform provides T ... Inc. Vyriad is a clinical-stage biotechnology company developing the next generation of targeted genetic therapies using engineered ...

To develop the next generation of in vivo T cell therapy, Novartis will leverage Vyriad's active targeting lentiviral vector platform to discover and develop new in vivo CAR-T cell therapy candidates.

It’s an interesting place to start both because it obviously addresses the overlap of generation and politics and because it gets at a fundamental aspect of generations: They are, in fact ...

The suspected madman behind a deadly stabbing spree in Manhattan Monday has a long criminal history — and had just walked free from Rikers Island a month before the terrifying attacks, The Post ...

“As part of our regular portfolio assessment, we have made the strategic decision to deprioritize ex vivo lentiviral-based ... but the earlier-generation technology has its share of problems ...